Αρχική World News The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not Be...

The Risk of irAEs After Immune Checkpoint Inhibitor Therapy May Not Be Elevated in Patients with Autoimmune Disease

No significant difference was observed in the number of immune-related adverse events (irAE) or the response following treatment with diverse immune checkpoint inhibitor (ICI) agents across several solid tumour types in patients with pre-existing autoimmune disease (AID) compared to patients without AID. These findings were presented at the ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021 held on 1-2 March.

Grisma Patel and a team of co-investigators from the University College London Hospitals NHS Foundation Trust in London, UK examined whether patients with autoimmune disease (AID) were at increased risk of AID flare or severe irAE, as is currently hypothesised, but unverified.

They provided evidence from records of ICIs use at a UK tertiary cancer centre by comparing irAE profiles and efficacy in patients with pre-existing AID to patients without AID in a 1:3 matched cohort for tumour-type and treatment. They conducted this single centre retrospective analysis of the electronic records of patients with solid tumours who were treated with an ICI from January 2017 to December 2020.

AID was well-controlled in all patients

Of the 562 treated patients, 15 had pre-existing AID that was well controlled. In this cohort, 6 patients were not receiving AID therapy whereas 9 patients were receiving hormone replacement, or topical agents and 3 patients were on immunosuppressive therapy; of these 2 received prednisolone at <10 mg, and one patient was on mesalazine.

In the AID cohort, 5 patients had inflammatory bowel disease, 3 had psoriasis, 2 each had rheumatoid arthritis or polymyalgia rheumatica, 4 had autoimmune endocrinopathies, and one patient each had lupus or sarcoidosis. Two co-existing AID were reported in 3 patients.

Patients in both cohorts were treated for gynaecological, colorectal, head and neck, Merkel cell, urothelial, or non-small cell lung cancer.

Treatment within a clinical study was administered to 4 patients in the AID cohort and 13 in the non-AID cohort while the remaining 11 and 32 patients in the respective cohorts received treatment outside of a clinical study. The majority of patients in the AID and non-AID cohorts (9 and 27, respectively) received pembrolizumab, while other ICIs administered to patients in the respective cohorts included nivolumab (2 and 6), nivolumab plus ipilimumab (2 and 6), atezolizumab (1 and 3), and durvalumab (1 and 3).

One-fifth of patients with AID had an irAE that was possibly linked to underlying disease

With ICI treatment, 3 of the 15 patients in the AID cohort experienced an irAE that was possibly linked to their underlying AID; of these patients one each had psoriasis, rheumatoid arthritis, and colitis.

No significant differences were found between the cohort of patients with AID and the cohort of 45 matched patients without AID regarding the number of irAEs (p = 0.5691) or the number of grade 3 to 5 irAEs (p = 0.42), In the respective cohorts, 9 versus 21 patients experienced no irAEs, 5 versus 17 had one, and one versus 7 patients had 2 irAEs.

The-Risk-of-irAEs-After-Immune-Checkpoint-Inhibitor-Therapy-May-Not-Be-Elevated-in-Patients-with-Autoimmune-Disease

Number of immune-related adverse events (irAEs) in the AID and no AID cohorts: Shown are the percentage of patients within each cohort vs total number of irAEs; no significant differences were found in the total number of irAEs between both cohorts (p = 0.57).

© Grisma Patel.

Similarly, no significant difference was observed in the best response to treatment between cohorts, (p=0.91). In the AID and non-AID cohorts, 7 versus 18 patients achieved complete or partial response, one versus 5 showed mixed response, two versus 5 showed stable disease, and 4 versus 15 patients experienced disease progression.

Conclusions

Based on the evidence from the electronic records of ICI-treated patients of a tertiary cancer centre the authors were able to conclude that, with treatment comprising several different ICIs, exacerbation of pre-existing AID was infrequent and did not result in severe toxicity.

They advised that patients with well-controlled AID could be considered for entry in clinical studies involving ICI.

This study did not receive external funding. 

Reference

31P – Patel G, Sawhney P, Ohana D, et al. Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience. ESMO Targeted Anticancer Therapies (TAT) Virtual Congress (1-2 March 2021).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում

«Քաղցկեղն իմ համայնքում»-ը Cancer.Net Blog շարքից է, որը ցույց է տալիս աշխարհում քաղցկեղի ազդեցությունը և թե ինչպես են մարդիկ աշխատում իրենց տարածաշրջանում քաղցկեղով մարդկանց...

Ovarian cancer screening trial did not save lives

“The effort from the start was to save lives of women with ovarian cancer. To build evidence for a screening programme that the NHS...

Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma

Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after...

Expressive Writing, What is It?

One of psychotherapy’s main beliefs is that putting thoughts and feelings into words may produce mental health benefits. Of course, this also applies to cancer...

Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer

May 12, 2021, by NCI Staff In triple-negative breast cancer (TNBC), tumor cells don't have estrogen receptors (ER), progesterone receptors (PR), or large amounts of...

‘Will cancer make me infertile?’ – That Cancer Conversation

For the first episode of That Cancer Conversation, we explore infertility and cancer. From teenage body worries to an intercontinental surrogacy story, we chat to...